Repligen Corp is primarily active in the biotechnology and life sciences industries.

Some of the main competitors of Repligen Corp in the market include Thermo Fisher Scientific, Merck KGaA, Danaher Corporation, and GE Healthcare.

Repligen Corp is a prominent bioprocessing company with a rich history. Founded in 1981, Repligen initially focused on the development of diagnostic products and later expanded its scope to include bioprocessing technologies. Over the years, the company has made significant contributions to the life sciences industry, offering innovative solutions for biomanufacturing needs. Today, Repligen is recognized for its high-quality products and services, serving customers globally. With a commitment to advancing bioprocessing efficiency and productivity, Repligen continues to drive innovation in the field, supporting the development and manufacturing of biologics.

Repligen Corp has achieved several significant milestones. The company successfully completed the acquisition of Spectrum Laboratories in 2012, expanding its product portfolio and enhancing its market presence. In 2014, Repligen received FDA approval for its flagship bioprocessing product, Protein A, which revolutionized the purification of monoclonal antibodies. The company continued its growth by acquiring the business unit of Novavax Inc. in 2015, strengthening its position in the bioprocessing market. Repligen Corp also reached a partnership agreement with Navigo Proteins GmbH in 2019, allowing the development of new affinity ligands. These achievements demonstrate Repligen Corp's dedication to innovation and market leadership.

Repligen Corp is primarily present in several countries and regions. These include the United States, Europe, and Asia.

Repligen Corp is a leading bioprocessing company committed to enhancing biologic drug manufacturing processes. The company's corporate philosophy revolves around key values such as innovation, quality, and collaboration. Repligen Corp strives to provide cutting-edge solutions to improve productivity, efficiency, and consistency in bioproduction through its advanced technologies and expertise. With a focus on customer satisfaction and a passion for advancing bioprocessing technologies, Repligen Corp aims to empower customers and contribute to making biologic medicines more accessible for patients worldwide.

Analysts currently set an average price target of 194,44 USD for the Repligen stock (median: 195,84 USD), implying +17,5 % versus the latest price. The consensus is based on 28 analyst ratings.

Repligen Koersdoelstellingen analisten 2026

28 analysts currently rate the Repligen stock: 23 recommend buying, 5 holding and 0 selling. For 2026, analysts expect Repligen to generate revenue of 827,04 Miljoen USD and earnings per share of 2,04 USD.

Repligen Koersdoelstellingen analisten 2026

Converted at the current exchange rate, the Repligen share trades at 144,12 EUR (166,83 USD).

The Repligen share (RGEN) is listed on 5 stock exchanges, including: NASDAQ (RGEN), Frankfurt (RGN.F), München (RGN.MU), Düsseldorf (RGN.DU), SIX (Zürich) (RGN.SW).

Repligen Corp is a leading biotech company specializing in the research, development, and manufacturing of products for bioproduction and cell therapy. The company was founded in 1981 and is headquartered in Waltham, Massachusetts. Repligen Corp's business model is based on four different divisions: bioproduction, chromatography, short-term culture media, and cell therapy. These divisions offer a wide range of products for the research and development community as well as the biopharmaceutical industry. The bioproduction division of Repligen Corp offers a variety of products for the production of recombinant proteins, antibodies, and other therapeutics. These include HGGE and Protein-A affinity resins, the TangenX® membrane separation portfolio, and the XCell™ ATF system for perfusion. The chromatography division of Repligen Corp offers a wide range of products for the purification of proteins and other biologics. These include protein-A affinity resins, reversed-phase resins, HIC and ion exchange resins, and more. The short-term culture media division of Repligen Corp specializes in the development of media for cell cultivation. These include the OptiCHO™, OptiPEAK TiterMAX®, and CellBoost™ portfolios. The cell therapy division of Repligen Corp offers strictly regulated products for clinical applications in cell therapy. These include Syntheglas™ peptides and SAVI™ cell therapy products for the treatment of inflammatory diseases in the gastrointestinal tract. Repligen Corp also offers services and support for its products, including technical consulting and support as well as product training. The company works closely with its customers to ensure that its products meet the specific requirements of the research and biopharmaceutical industry. Overall, Repligen Corp has a strong business model based on the development of innovative products for bioproduction and cell therapy. The company is committed to advancing the development of its products and actively participating in the expansion of the bioproduction industry. Answer: Repligen Corp is a biotech company specializing in the research, development, and manufacturing of products for bioproduction and cell therapy. They offer a range of products for protein production, protein purification, cell cultivation, and cell therapy. The company provides services, support, and product training and aims to contribute to the growth of the bioproduction industry.

De verwachte omzet van Repligen bedraagt 827,04 Miljoen USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.

De verwachte winst van Repligen bedraagt 115,47 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.

De koers-winstverhouding (P/E) van Repligen bedraagt momenteel 81,66. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Repligen-aandeel in te schatten.

De koers-omzetverhouding (P/S) van Repligen bedraagt momenteel 11,40. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Repligen-aandeel.

De Eulerpool Kwaliteitsscore voor Repligen is 4/10.

De ISIN van Repligen is US7599161095. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.

De WKN van Repligen is 870980. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.

Het tickersymbool van Repligen is RGEN. Onder dit beurstickersymbool wordt het Repligen-aandeel op de beurs verhandeld.

Repligen betaalde de afgelopen 0 jaar elk jaar dividend.

Repligen wordt toegewezen aan de sector 'Gezondheid'.

De dividenden van Repligen worden in USD uitgekeerd.